Cargando…

In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer

Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Paiva, Karen L. R., Radicchi, Marina A., Báo, Sônia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370415/
https://www.ncbi.nlm.nih.gov/pubmed/35956870
http://dx.doi.org/10.3390/molecules27154920
_version_ 1784766789932023808
author Paiva, Karen L. R.
Radicchi, Marina A.
Báo, Sônia N.
author_facet Paiva, Karen L. R.
Radicchi, Marina A.
Báo, Sônia N.
author_sort Paiva, Karen L. R.
collection PubMed
description Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug’s action in the MDA-MB-231 cell line.
format Online
Article
Text
id pubmed-9370415
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93704152022-08-12 In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer Paiva, Karen L. R. Radicchi, Marina A. Báo, Sônia N. Molecules Article Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug’s action in the MDA-MB-231 cell line. MDPI 2022-08-02 /pmc/articles/PMC9370415/ /pubmed/35956870 http://dx.doi.org/10.3390/molecules27154920 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Paiva, Karen L. R.
Radicchi, Marina A.
Báo, Sônia N.
In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
title In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
title_full In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
title_fullStr In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
title_full_unstemmed In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
title_short In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
title_sort in vitro evaluation of nls-dtx activity in triple-negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370415/
https://www.ncbi.nlm.nih.gov/pubmed/35956870
http://dx.doi.org/10.3390/molecules27154920
work_keys_str_mv AT paivakarenlr invitroevaluationofnlsdtxactivityintriplenegativebreastcancer
AT radicchimarinaa invitroevaluationofnlsdtxactivityintriplenegativebreastcancer
AT baosonian invitroevaluationofnlsdtxactivityintriplenegativebreastcancer